A phase III study of oral VK 2735 for Obesity
Latest Information Update: 08 Mar 2026
At a glance
- Drugs VK 2735 (Primary)
- Indications Obesity
- Focus Therapeutic Use
Most Recent Events
- 08 Mar 2026 New trial record
- 11 Feb 2026 According to Viking Therapeutics media release, the company plans to advance oral VK2735 into Phase 3 development for obesity, expected to begin in 3Q26.